Open access
2,531
Views
1
CrossRef citations to date
0
Altmetric
Original Research
A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors
Miguel Escobara University of Texas Health Science Center, Houston, TX, USACorrespondence[email protected]
https://orcid.org/0000-0002-2944-0240View further author information
Michael Bullanob Takeda Pharmaceuticals USA, Lexington, MA, USA
https://orcid.org/0000-0002-9961-4576View further author information
Ali G. Mokdadb Takeda Pharmaceuticals USA, Lexington, MA, USA
https://orcid.org/0000-0002-4839-0373View further author information
Jorge Caicedob Takeda Pharmaceuticals USA, Lexington, MA, USA
https://orcid.org/0000-0002-5816-568XView further author information
Bob G. Schultzb Takeda Pharmaceuticals USA, Lexington, MA, USA
https://orcid.org/0000-0002-7023-8378View further author information
Qi Fanb Takeda Pharmaceuticals USA, Lexington, MA, USA
https://orcid.org/0000-0002-6578-0330View further author information
Sumit Vermac STATinMED, Ann Arbor, MI, USA
https://orcid.org/0000-0003-2815-2201View further author information
Pages 467-474
|
Received 21 Feb 2023, Accepted 25 Mar 2023, Published online: 28 Apr 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.